| Full text | |
| Author(s): |
Thomaz, Matheus De Lucca
;
Vieira, Carolina Pinto
;
Caris, Juciene Aparecida
;
Marques, Maria Paula
;
Rocha, Adriana
;
Paz, Tiago Antunes
;
Rezende, Rosamar Eulira Fontes
;
Lanchote, Vera Lucia
Total Authors: 8
|
| Document type: | Journal article |
| Source: | PHARMACEUTICALS; v. 17, n. 7, p. 14-pg., 2024-07-01. |
| Abstract | |
This study aims to evaluate the impact of liver fibrosis stages of chronic infection with hepatitis C virus (HCV) on the in vivo activity of organic cation transporters (hepatic OCT1 and renal OCT2) using metformin (MET) as a probe drug. Participants allocated in Group 1 (n = 15, mild to moderate liver fibrosis) or 2 (n = 13, advanced liver fibrosis and cirrhosis) received a single MET 50 mg oral dose before direct-acting antiviral (DAA) drug treatment (Phase 1) and 30 days after achieving sustained virologic response (Phase 2). OCT1/2 activity (MET AUC0-24) was found to be reduced by 25% when comparing the two groups in Phase 2 (ratio 0.75 (0.61-0.93), p < 0.05) but not in Phase 1 (ratio 0.81 (0.66-0.98), p > 0.05). When Phases 1 and 2 were compared, no changes were detected in both Groups 1 (ratio 1.10 (0.97-1.24), p > 0.05) and 2 (ratio 1.03 (0.94-1.12), p > 0.05). So, this study shows a reduction of approximately 25% in the in vivo activity of OCT1/2 in participants with advanced liver fibrosis and cirrhosis after achieving sustained virologic response and highlights that OCT1/2 in vivo activity depends on the liver fibrosis stage of chronic HCV infection. (AU) | |
| FAPESP's process: | 18/05616-3 - Clinical pharmacokinetics in infectious diseases |
| Grantee: | Vera Lúcia Lanchote |
| Support Opportunities: | Research Projects - Thematic Grants |